Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Preferred Stock Liabilities: 2012-2024

Historic Preferred Stock Liabilities for Northwest Biotherapeutics (NWBO) over the last 6 years, with Dec 2024 value amounting to $15.5 million.

  • Northwest Biotherapeutics' Preferred Stock Liabilities fell 15.60% to $13.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.4 million, marking a year-over-year decrease of 15.60%. This contributed to the annual value of $15.5 million for FY2024, which is 17.15% down from last year.
  • Latest data reveals that Northwest Biotherapeutics reported Preferred Stock Liabilities of $15.5 million as of FY2024, which was down 17.15% from $18.7 million recorded in FY2023.
  • In the past 5 years, Northwest Biotherapeutics' Preferred Stock Liabilities ranged from a high of $23.1 million in FY2022 and a low of $15.5 million during FY2024.
  • Its 3-year average for Preferred Stock Liabilities is $19.1 million, with a median of $18.7 million in 2023.
  • Data for Northwest Biotherapeutics' Preferred Stock Liabilities shows a maximum YoY decreased of 18.83% (in 2023) over the last 5 years.
  • Over the past 3 years, Northwest Biotherapeutics' Preferred Stock Liabilities (Yearly) stood at $23.1 million in 2022, then declined by 18.83% to $18.7 million in 2023, then decreased by 17.15% to $15.5 million in 2024.